Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Topics: Population, Cancer, Breast cancer, Medicine, Metastatic breast cancer
Papers published on a yearly basis
Papers
More filters
Sheba Medical Center1, Vita-Salute San Raffaele University2, Katholieke Universiteit Leuven3, Hebron University4, Fox Chase Cancer Center5, Samsung Medical Center6, University College London7, Seoul National University Hospital8, Ruhr University Bochum9, Memorial Sloan Kettering Cancer Center10, AstraZeneca11, Merck & Co.12, University of Chicago13
TL;DR: Results from POLO, the first phase 3 trial to evaluate maintenance therapy with the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib (O) in patients with metastatic pancreatic cancer, show encouraging results.
Abstract: 378Background: POLO is the first phase 3 trial to evaluate maintenance therapy with the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib (O) in patients with metastatic pancreatic cancer (mPa...
54 citations
TL;DR: Although the studies are of poor quality, the rate of major congenital abnormalities in the newborn exposed to statins during pregnancy is no higher than the expected when compared with overall risk population.
Abstract: ImportanceWe have performed a systematic search to summarize the role of statins for preventing and treating severe preeclampsia.ObjectiveThe aim of this study was to examine whether pravastatin is a useful and safe alternative for treating preeclampsia during pregnancy.Evidence AcquisitionA systema
54 citations
Hebron University1, Aix-Marseille University2, University of Paris-Sud3, Cross Cancer Institute4, New York University5, Asan Medical Center6, Harvard University7, Oslo University Hospital8, VU University Medical Center9, University Medical Center Groningen10, Seoul National University Hospital11, Samsung Medical Center12, Novartis13, University of California, Los Angeles14
TL;DR: AUY922 is active in patients with NSCLC, particularly among patients with ALK rearrangements and EGFR mutations, particularly amongst patients with AlK rearranged mutations.
54 citations
Université libre de Bruxelles1, Hebron University2, Breast International Group3, Sheba Medical Center4, Memorial Sloan Kettering Cancer Center5, University of Milan6, Institute of Cancer Research7, Medical University of Graz8, Champalimaud Foundation9, Pompeu Fabra University10, Centre Hospitalier de Luxembourg11, European Organisation for Research and Treatment of Cancer12, Katholieke Universiteit Leuven13, Edinburgh Cancer Research Centre14, Sahlgrenska University Hospital15, Paracelsus Private Medical University of Salzburg16, University of Genoa17, Fred Hutchinson Cancer Research Center18, Princess Margaret Cancer Centre19, Peter MacCallum Cancer Centre20, Wellcome Trust Sanger Institute21
TL;DR: AURORA as discussed by the authors aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases.
Abstract: AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 targeted gene sequencing, 152 RNA sequencing, 67 single nucleotide polymorphism arrays), we found a driver role for GATA1 and MEN1 somatic mutations. Metastases were enriched in ESR1, PTEN, CDH1, PIK3CA, and RB1 mutations; MDM4 and MYC amplifications; and ARID1A deletions. An increase in clonality was observed in driver genes such as ERBB2 and RB1. Intrinsic subtype switching occurred in 36% of cases. Luminal A/B to HER2-enriched switching was associated with TP53 and/or PIK3CA mutations. Metastases had lower immune score and increased immune-permissive cells. High tumor mutational burden correlated to shorter time to relapse in HR+/HER2− cancers. ESCAT tier I/II alterations were detected in 51% of patients and matched therapy was used in 7%. Integration of multi-omics analyses in clinical practice could affect treatment strategies in MBC. Significance: The AURORA program, through the genomic and transcriptomic analyses of matched primary and metastatic samples from 381 patients with breast cancer, coupled with prospectively collected clinical data, identified genomic alterations enriched in metastases and prognostic biomarkers. ESCAT tier I/II alterations were detected in more than half of the patients. This article is highlighted in the In This Issue feature, p. 2659
53 citations
Katholieke Universiteit Leuven1, University of Southern California2, Kyorin University3, Hebron University4, Ludwig Maximilian University of Munich5, Imperial College London6, Palacký University, Olomouc7, Ministry of Science and Innovation8, University of Debrecen9, Merck KGaA10, Merck Serono11, Sarah Cannon Research Institute12
TL;DR: Evo is a hypoxia-activated prodrug of Br-IPM that is preferentially activated under hypoxic conditions that is associated with disease progression and poor prognosis in PDAC.
Abstract: 4007Background: Hypoxia in PDAC is associated with disease progression and poor prognosis. Evo is a hypoxia-activated prodrug of Br-IPM that is preferentially activated under hypoxic conditions. Th...
53 citations
Authors
Showing all 2723 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| José Baselga | 156 | 707 | 122498 |
| M. I. Martínez | 134 | 1251 | 79885 |
| Josep Tabernero | 111 | 803 | 68982 |
| Jordi Rello | 103 | 694 | 35994 |
| Xavier Montalban | 95 | 762 | 52842 |
| James M. Downey | 91 | 381 | 29506 |
| Enriqueta Felip | 83 | 622 | 53364 |
| Joaquim Bellmunt | 82 | 660 | 41472 |
| Joan Montaner | 80 | 489 | 22413 |
| Marc Miravitlles | 76 | 651 | 25671 |
| David H. Salat | 75 | 241 | 36779 |
| Eduard Gratacós | 75 | 531 | 20178 |
| Alex Rovira | 74 | 356 | 19586 |
| Ramon Bataller | 72 | 283 | 19316 |
| Maria Buti | 71 | 493 | 26596 |